Clinical Trial

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2025-05-27; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2025-10-17
Trial Details
NCT Number NCT07006727
Lead Sponsor Novartis Pharmaceuticals
Conditions Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Enrollment 116 participants
Start Date 2025-10-16
Primary Completion 2031-08-29 (estimated)
Study Completion 2031-08-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-28